Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Peter Kraft, Ph.D.

Co-Author

This page shows the publications co-authored by Peter Kraft and Meir Stampfer.
Connection Strength

3.644
  1. Genetic and Circulating Biomarker Data Improve Risk Prediction for Pancreatic Cancer in the General Population. Cancer Epidemiol Biomarkers Prev. 2020 05; 29(5):999-1008.
    View in: PubMed
    Score: 0.224
  2. A comprehensive survey of genetic variation in 20,691 subjects from four large cohorts. PLoS One. 2017; 12(3):e0173997.
    View in: PubMed
    Score: 0.181
  3. Association of prostate cancer risk variants with gene expression in normal and tumor tissue. Cancer Epidemiol Biomarkers Prev. 2015 Jan; 24(1):255-60.
    View in: PubMed
    Score: 0.153
  4. Prostate cancer (PCa) risk variants and risk of fatal PCa in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. Eur Urol. 2014 Jun; 65(6):1069-75.
    View in: PubMed
    Score: 0.145
  5. Association of type 2 diabetes susceptibility variants with advanced prostate cancer risk in the Breast and Prostate Cancer Cohort Consortium. Am J Epidemiol. 2012 Dec 15; 176(12):1121-9.
    View in: PubMed
    Score: 0.134
  6. Common genetic variants in prostate cancer risk prediction--results from the NCI Breast and Prostate Cancer Cohort Consortium (BPC3). Cancer Epidemiol Biomarkers Prev. 2012 Mar; 21(3):437-44.
    View in: PubMed
    Score: 0.126
  7. Replication of five prostate cancer loci identified in an Asian population--results from the NCI Breast and Prostate Cancer Cohort Consortium (BPC3). Cancer Epidemiol Biomarkers Prev. 2012 Jan; 21(1):212-6.
    View in: PubMed
    Score: 0.124
  8. Genome-wide association study identifies new prostate cancer susceptibility loci. Hum Mol Genet. 2011 Oct 01; 20(19):3867-75.
    View in: PubMed
    Score: 0.122
  9. Characterizing associations and SNP-environment interactions for GWAS-identified prostate cancer risk markers--results from BPC3. PLoS One. 2011 Feb 24; 6(2):e17142.
    View in: PubMed
    Score: 0.119
  10. Eighteen insulin-like growth factor pathway genes, circulating levels of IGF-I and its binding protein, and risk of prostate and breast cancer. Cancer Epidemiol Biomarkers Prev. 2010 Nov; 19(11):2877-87.
    View in: PubMed
    Score: 0.115
  11. Toll-like receptor signaling pathway variants and prostate cancer mortality. Cancer Epidemiol Biomarkers Prev. 2009 Jun; 18(6):1859-63.
    View in: PubMed
    Score: 0.105
  12. Genetic variation in the HSD17B1 gene and risk of prostate cancer. PLoS Genet. 2005 Nov; 1(5):e68.
    View in: PubMed
    Score: 0.082
  13. Prediagnostic Inflammation and Pancreatic Cancer Survival. J Natl Cancer Inst. 2021 Sep 04; 113(9):1186-1193.
    View in: PubMed
    Score: 0.062
  14. Associations of dairy intake with risk of mortality in women and men: three prospective cohort studies. BMJ. 2019 11 27; 367:l6204.
    View in: PubMed
    Score: 0.054
  15. Circulating vitamin D concentrations and risk of breast and prostate cancer: a Mendelian randomization study. Int J Epidemiol. 2019 10 01; 48(5):1416-1424.
    View in: PubMed
    Score: 0.054
  16. Family history of cancer, Ashkenazi Jewish ancestry, and pancreatic cancer risk. Br J Cancer. 2019 04; 120(8):848-854.
    View in: PubMed
    Score: 0.052
  17. Prediagnosis Use of Statins Associates With Increased Survival Times of Patients With Pancreatic Cancer. Clin Gastroenterol Hepatol. 2018 08; 16(8):1300-1306.e3.
    View in: PubMed
    Score: 0.048
  18. Statin use and pancreatic cancer risk in two prospective cohort studies. J Gastroenterol. 2018 Aug; 53(8):959-966.
    View in: PubMed
    Score: 0.048
  19. Regular Use of Aspirin or Non-Aspirin Nonsteroidal Anti-Inflammatory Drugs Is Not Associated With Risk of Incident Pancreatic Cancer in Two Large Cohort Studies. Gastroenterology. 2018 04; 154(5):1380-1390.e5.
    View in: PubMed
    Score: 0.047
  20. Genomic analyses identify hundreds of variants associated with age at menarche and support a role for puberty timing in cancer risk. Nat Genet. 2017 Jun; 49(6):834-841.
    View in: PubMed
    Score: 0.045
  21. Cigarette Smoking and Pancreatic Cancer Survival. J Clin Oncol. 2017 Jun 01; 35(16):1822-1828.
    View in: PubMed
    Score: 0.045
  22. Interactions Between Genome-Wide Significant Genetic Variants and Circulating Concentrations of 25-Hydroxyvitamin D in Relation to Prostate Cancer Risk in the National Cancer Institute BPC3. Am J Epidemiol. 2017 03 15; 185(6):452-464.
    View in: PubMed
    Score: 0.045
  23. Pancreatic Cancer Risk Associated with Prediagnostic Plasma Levels of Leptin and Leptin Receptor Genetic Polymorphisms. Cancer Res. 2016 12 15; 76(24):7160-7167.
    View in: PubMed
    Score: 0.044
  24. Leucocyte telomere length, genetic variants at the TERT gene region and risk of pancreatic cancer. Gut. 2017 06; 66(6):1116-1122.
    View in: PubMed
    Score: 0.044
  25. PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. J Med Genet. 2016 12; 53(12):800-811.
    View in: PubMed
    Score: 0.044
  26. Prediagnostic Plasma 25-Hydroxyvitamin D and Pancreatic Cancer Survival. J Clin Oncol. 2016 08 20; 34(24):2899-905.
    View in: PubMed
    Score: 0.043
  27. Cross-Cancer Genome-Wide Analysis of Lung, Ovary, Breast, Prostate, and Colorectal Cancer Reveals Novel Pleiotropic Associations. Cancer Res. 2016 09 01; 76(17):5103-14.
    View in: PubMed
    Score: 0.042
  28. Circulating Metabolites and Survival Among Patients With Pancreatic Cancer. J Natl Cancer Inst. 2016 Jun; 108(6):djv409.
    View in: PubMed
    Score: 0.042
  29. Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for Thirteen Cancer Types. J Natl Cancer Inst. 2015 Dec; 107(12):djv279.
    View in: PubMed
    Score: 0.041
  30. Genome-wide association study of prostate cancer-specific survival. Cancer Epidemiol Biomarkers Prev. 2015 Nov; 24(11):1796-800.
    View in: PubMed
    Score: 0.041
  31. ABO blood group alleles and prostate cancer risk: Results from the breast and prostate cancer cohort consortium (BPC3). Prostate. 2015 Nov; 75(15):1677-81.
    View in: PubMed
    Score: 0.040
  32. Integration of multiethnic fine-mapping and genomic annotation to prioritize candidate functional SNPs at prostate cancer susceptibility regions. Hum Mol Genet. 2015 Oct 01; 24(19):5603-18.
    View in: PubMed
    Score: 0.040
  33. Survival among patients with pancreatic cancer and long-standing or recent-onset diabetes mellitus. J Clin Oncol. 2015 Jan 01; 33(1):29-35.
    View in: PubMed
    Score: 0.038
  34. Circadian clock genes and risk of fatal prostate cancer. Cancer Causes Control. 2015 Jan; 26(1):25-33.
    View in: PubMed
    Score: 0.038
  35. A genome-wide pleiotropy scan for prostate cancer risk. Eur Urol. 2015 Apr; 67(4):649-57.
    View in: PubMed
    Score: 0.038
  36. Elevation of circulating branched-chain amino acids is an early event in human pancreatic adenocarcinoma development. Nat Med. 2014 10; 20(10):1193-1198.
    View in: PubMed
    Score: 0.038
  37. A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. Nat Genet. 2014 Oct; 46(10):1103-9.
    View in: PubMed
    Score: 0.038
  38. Parent-of-origin-specific allelic associations among 106 genomic loci for age at menarche. Nature. 2014 Oct 02; 514(7520):92-97.
    View in: PubMed
    Score: 0.038
  39. Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. Hum Mol Genet. 2014 Dec 15; 23(24):6616-33.
    View in: PubMed
    Score: 0.038
  40. Androgen receptor CAG repeat polymorphism and risk of TMPRSS2:ERG-positive prostate cancer. Cancer Epidemiol Biomarkers Prev. 2014 Oct; 23(10):2027-31.
    View in: PubMed
    Score: 0.037
  41. Insulin-like growth factor pathway genetic polymorphisms, circulating IGF1 and IGFBP3, and prostate cancer survival. J Natl Cancer Inst. 2014 Jun; 106(6):dju085.
    View in: PubMed
    Score: 0.037
  42. Prediagnostic body mass index and pancreatic cancer survival. J Clin Oncol. 2013 Nov 20; 31(33):4229-34.
    View in: PubMed
    Score: 0.036
  43. Hyperglycemia, insulin resistance, impaired pancreatic ß-cell function, and risk of pancreatic cancer. J Natl Cancer Inst. 2013 Jul 17; 105(14):1027-35.
    View in: PubMed
    Score: 0.035
  44. Inflammatory plasma markers and pancreatic cancer risk: a prospective study of five U.S. cohorts. Cancer Epidemiol Biomarkers Prev. 2013 May; 22(5):855-61.
    View in: PubMed
    Score: 0.034
  45. Genetic variation in the vitamin d pathway in relation to risk of prostate cancer--results from the breast and prostate cancer cohort consortium. Cancer Epidemiol Biomarkers Prev. 2013 Apr; 22(4):688-96.
    View in: PubMed
    Score: 0.034
  46. A prospective study of plasma adiponectin and pancreatic cancer risk in five US cohorts. J Natl Cancer Inst. 2013 Jan 16; 105(2):95-103.
    View in: PubMed
    Score: 0.034
  47. Common genetic variation of the calcium-sensing receptor and lethal prostate cancer risk. Cancer Epidemiol Biomarkers Prev. 2013 Jan; 22(1):118-26.
    View in: PubMed
    Score: 0.033
  48. Vitamin D-related genetic variation, plasma vitamin D, and risk of lethal prostate cancer: a prospective nested case-control study. J Natl Cancer Inst. 2012 May 02; 104(9):690-9.
    View in: PubMed
    Score: 0.032
  49. Interactions between genome-wide significant genetic variants and circulating concentrations of insulin-like growth factor 1, sex hormones, and binding proteins in relation to prostate cancer risk in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. Am J Epidemiol. 2012 May 01; 175(9):926-35.
    View in: PubMed
    Score: 0.032
  50. Plasma 25-hydroxyvitamin D and risk of pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2012 Jan; 21(1):82-91.
    View in: PubMed
    Score: 0.031
  51. Genetic variation in the toll-like receptor 4 and prostate cancer incidence and mortality. Prostate. 2012 Feb 01; 72(2):209-16.
    View in: PubMed
    Score: 0.030
  52. mRNA expression signature of Gleason grade predicts lethal prostate cancer. J Clin Oncol. 2011 Jun 10; 29(17):2391-6.
    View in: PubMed
    Score: 0.030
  53. Association of KLK3 (PSA) genetic variants with prostate cancer risk and PSA levels. Carcinogenesis. 2011 Jun; 32(6):853-9.
    View in: PubMed
    Score: 0.030
  54. Genome-wide association study of prostate cancer mortality. Cancer Epidemiol Biomarkers Prev. 2010 Nov; 19(11):2869-76.
    View in: PubMed
    Score: 0.029
  55. A large study of androgen receptor germline variants and their relation to sex hormone levels and prostate cancer risk. Results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. J Clin Endocrinol Metab. 2010 Sep; 95(9):E121-7.
    View in: PubMed
    Score: 0.028
  56. A comprehensive analysis of common IGF1, IGFBP1 and IGFBP3 genetic variation with prospective IGF-I and IGFBP-3 blood levels and prostate cancer risk among Caucasians. Hum Mol Genet. 2010 Aug 01; 19(15):3089-101.
    View in: PubMed
    Score: 0.028
  57. A large prospective study of SEP15 genetic variation, interaction with plasma selenium levels, and prostate cancer risk and survival. Cancer Prev Res (Phila). 2010 May; 3(5):604-10.
    View in: PubMed
    Score: 0.028
  58. PTGS2 and IL6 genetic variation and risk of breast and prostate cancer: results from the Breast and Prostate Cancer Cohort Consortium (BPC3). Carcinogenesis. 2010 Mar; 31(3):455-61.
    View in: PubMed
    Score: 0.027
  59. CYP19A1 genetic variation in relation to prostate cancer risk and circulating sex hormone concentrations in men from the Breast and Prostate Cancer Cohort Consortium. Cancer Epidemiol Biomarkers Prev. 2009 Oct; 18(10):2734-44.
    View in: PubMed
    Score: 0.027
  60. Quantitative trait loci predicting circulating sex steroid hormones in men from the NCI-Breast and Prostate Cancer Cohort Consortium (BPC3). Hum Mol Genet. 2009 Oct 01; 18(19):3749-57.
    View in: PubMed
    Score: 0.026
  61. Circulating prediagnostic interleukin-6 and C-reactive protein and prostate cancer incidence and mortality. Int J Cancer. 2009 Jun 01; 124(11):2683-9.
    View in: PubMed
    Score: 0.026
  62. Fine mapping and functional analysis of a common variant in MSMB on chromosome 10q11.2 associated with prostate cancer susceptibility. Proc Natl Acad Sci U S A. 2009 May 12; 106(19):7933-8.
    View in: PubMed
    Score: 0.026
  63. Variation in KLK genes, prostate-specific antigen and risk of prostate cancer. Nat Genet. 2008 Sep; 40(9):1032-4; author reply 1035-6.
    View in: PubMed
    Score: 0.025
  64. CYP17 genetic variation and risk of breast and prostate cancer from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3). Cancer Epidemiol Biomarkers Prev. 2007 Nov; 16(11):2237-46.
    View in: PubMed
    Score: 0.024
  65. Sequence variants of estrogen receptor beta and risk of prostate cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. Cancer Epidemiol Biomarkers Prev. 2007 Oct; 16(10):1973-81.
    View in: PubMed
    Score: 0.023
  66. A common 8q24 variant in prostate and breast cancer from a large nested case-control study. Cancer Res. 2007 Apr 01; 67(7):2951-6.
    View in: PubMed
    Score: 0.023
  67. A candidate gene approach to searching for low-penetrance breast and prostate cancer genes. Nat Rev Cancer. 2005 12; 5(12):977-85.
    View in: PubMed
    Score: 0.021
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.